{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:06:50Z","timestamp":1787954810530,"version":"build-2784847793"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20181238"],"award-info":[{"award-number":["BK20181238"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of stereotactic body radiotherapy (SBRT) targeting the primary tumor for liver-only oligometastatic pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared the efficacy and safety of SBRT plus chemotherapy with chemotherapy alone in patients with liver-only oligometastatic pancreatic cancer. The populations were balanced by propensity score-weighted and propensity score-matched analyses based on baseline variables. The primary outcome was overall survival (OS). The secondary outcomes included progression free survival (PFS), local progression, metastatic progression and symptomatic local control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This is a retrospective study of 89 pancreatic cancer patients with liver-only oligometastasis. Overall, 34 (38.2%) and 55 (61.8%) patients received SBRT plus chemotherapy and chemotherapy alone, respectively. After propensity score matching, 1-year OS rate was 34.0% (95%CI, 17.8-65.1%) in the SBRT plus chemotherapy group and 16.5% (95%CI, 5.9-46.1%) in chemotherapy alone group (P=0.115). The 6-month PFS rate was 29.4% (95%CI, 15.4-56.1) in SBRT plus chemotherapy and 20.6% (95%CI, 8.8-48.6) in chemotherapy alone group (P=0.468), respectively. Further subgroup analysis indicated that the addition of SBRT improved OS in patients with primary tumor located in the head of pancreas (stratified HR, 0.28; 95% CI, 0.09 to 0.90) or good performance status (stratified HR, 0.24; 95% CI, 0.07 to 0.86). In terms of disease control, SBRT delayed local progression of pancreas (P=0.008), but not distant metastatic progression (P=0.56). Besides, SBRT offered significant abdominal\/back pain relief (P=0.016) with acceptable toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The addition of SBRT to chemotherapy in patients with liver-only oligometastatic pancreatic cancer improves the OS of those with primary tumor located in the head of pancreas or good performance status. In addition, it is a safe and effective method for local progression control and local symptomatic palliation in patients with metastatic pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.659987","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:19:40Z","timestamp":1622074780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaoqin","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zetian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic Cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30314-5","article-title":"Safety and Tolerability of the First-in-Class Agent CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer: A Single-Centre, Open-Label, Dose-Escalation, Phase 1 Trial","volume":"18","author":"Alistar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3322\/caac.21626","article-title":"Multidisciplinary Standards of Care and Recent Progress in Pancreatic Ductal Adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA: A Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.12.020","article-title":"Current Progress in Immunotherapy for Pancreatic Cancer","volume":"381","author":"Foley","year":"2016","journal-title":"Cancer Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group\u2013directed Intergroup Trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2147\/JPR.S167994","article-title":"Stereotactic Radiotherapy of Pancreatic Cancer: A Systematic Review on Pain Relief","volume":"11","author":"Buwenge","year":"2018","journal-title":"J Pain Res"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.semradonc.2017.02.005","article-title":"Integration of Stereotactic Body Radiation Therapy Into the Multidisciplinary Management of Pancreatic Cancer","volume-title":"Semin Radiat Oncol","author":"Rosati","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.semradonc.2013.11.008","article-title":"Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer","volume-title":"Semin Radiat Oncol","author":"Trakul","year":"2014"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.12.012","article-title":"Clinical Results of Stereotactic Body Radiotherapy (SBRT) in the Treatment of Isolated Local Recurrence of Pancreatic Cancer After R0 Surgery: A Retrospective Study","volume":"43","author":"Comito","year":"2017","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-Wait Approach Versus Surgical Resection After Chemoradiotherapy for Patients With Rectal Cancer (the OnCoRe Project): A Propensity-Score Matched Cohort Analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing Inverse Probability Weights for Marginal Structural Models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database","volume":"36","author":"Rajyaguru","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma (MS01): A Multicentre Randomised Trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-016-9909-2","article-title":"Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer","volume":"49","author":"Lischalk","year":"2018","journal-title":"J gastrointestinal Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.02.010","article-title":"The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma","volume":"10","author":"Koong","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic Ablative Radiotherapy Versus Standard of Care Palliative Treatment in Patients With Oligometastatic Cancers (SABR-COMET): A Randomised, Phase 2, Open-Label Trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.07.2251","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial","volume":"108","author":"Palma","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"B29","article-title":"Pancreatic Cancer: Diagnosis and Management","volume":"73","author":"Freelove","year":"2006","journal-title":"Am Family physician"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.3748\/wjg.v21.i26.8156","article-title":"Stereotactic Body Radiotherapy Using CyberKnife for Locally Advanced Unresectable and Metastatic Pancreatic Cancer","volume":"21","author":"Su","year":"2015","journal-title":"World J Gastroenterol: WJG"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.659987\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:19:46Z","timestamp":1622074786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.659987\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":30,"alternative-id":["10.3389\/fonc.2021.659987"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.659987","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"article-number":"659987"}}